Market Highlights:
The global neuroblastoma is
anticipated to hold a market value of 2.60 billion in 2017 and is expected to
grow at a CAGR of 3.7% during the forecast period. Neuroblastoma is a childhood
cancer most commonly occurs in children below the age of 5 years. The neuroblast
may cause due to the immature cell growth or mutation in the gene responsible
for controlling cell proliferation. The increasing cases of childhood cancer,
rising research on neuroblastoma treatment and increasing spending on cancer
treatment is expected to drive market growth over the forecast period.
According to the American Society of Clinical Oncology (ASCO) April 2018
publication, every year, more than 700 children get diagnosed with
neuroblastoma in the US and it is also indicated that neuroblastoma is the most
common cancer in children younger than 1 year. It is more commonly found in
boys compare to girls. The increasing cases of childhood cancer boost market
growth during the forecast period.
Despite the drivers, shortage of
trained healthcare specialists and the high cost of this therapy can restrain
the Neuroblastoma
Market growth over the assessment period.
Key Players:
United
Therapeutics Corp., APEIRON Biologics AG, LUMITOS AG, NANTGE Healthcare, Pfizer
Inc., GL Pharm Tech Corporation, Aetna Inc, RxStrategies, Inc
Segmentation:
·
The
global neuroblastoma market has been segmented into diagnostics, treatment, and
end user.
·
The
market, on the basis of diagnostics, has been segmented into various tests,
MIBG scan, imaging, and biopsy. The tests are further sub-segmented into bone
marrow, tissue, urine, and blood.
·
The
market, by treatment, has been segmented into surgery, chemotherapy, radiation
therapy, stem cell transplant, immunotherapy, and monoclonal antibody treatment.
·
On
the basis of end user, the global neuroblastoma market has been segmented into
hospitals ambulatory surgical centers, diagnostic centers, research centers,
and others.
Regional Analysis:
Geographically, the Americas is
expected to dominate the global neuroblastoma market owing to the presence of
well-developed healthcare sector, rising prevalence of infant cancer cases, and
growing expenditure for the healthcare sector. Europe is expected to hold the
second largest position in the global neuroblastoma market owing to the growing
number of child healthcare centers for cancer treatment and raising awareness
about the treatment for neuroblastoma. According to the Cancer Research
UK May 2018 publication, around 100 infants are detected with neuroblastoma
every year in the UK. This provides favorable backgrounds for the neuroblastoma
market to grow.
Asia-Pacific is expected to be the
fastest growing market owing to the increasing children cancer base and
increasing developments in the healthcare segment.
According to the Neuroblastoma
Australia organization October 2018 article, every year approximately 40 cases
of neuroblastoma are indicated in Australia due to some unknown genetic
problems which will support the market growth.
Furthermore, the Middle Eastern and
African region is expected to account for the least market share in the global
market.
Comments
Post a Comment